沃森生物(300142.SZ):雙價HPV疫苗目前處於市場拓展和下沉階段,繼續優化銷售佈局,爭取加快突破
格隆匯8月17日丨有投資者向沃森生物(300142.SZ)提問,“公司HPV2價的疫苗能滿足目前招標省份的需求嗎?很久不見官方簽發了,這是什麼原因呢?公司是否會因為滿足招標省份需求,而放慢全國市場的鋪貨進展呢?”
沃森生物回覆稱,公司雙價HPV疫苗目前處於市場拓展和下沉階段,公司將繼續優化銷售佈局,爭取加快突破,努力實現產銷量的持續提升。同時,公司產品競爭策略會根據市場情況持續動態調整。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.